Kurt Graves, new i2o Therapeutics CEO
August 29, 2023 06:46 AM EDT
People
Financing
Startups

i2o Ther­a­peu­tics clos­es $46M Se­ries A, names Kurt Graves as CEO and ac­quires Intar­cia’s twice-re­ject­ed di­a­betes as­set

Reynald Castañeda

Deputy Editor

In a slew of com­pa­ny up­dates, i2o Ther­a­peu­tics has closed a Se­ries A raise worth $46 mil­lion from biotech in­vestors and named Kurt Graves as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times